NASDAQ:ETNB
89bio, Inc. Stock Company Profile
$8.94
+0.310 (+3.59%)
At Close: May 20, 2024
Information
142 Sansome Street, 2nd Floor
San Francisco CA 94104
415 432 9270
www.89bio.com
Industry: Biotechnology
Sector: Healthcare
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
